Is Diamedica Therapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: DMAC) stock is to Buy DMAC stock.
Out of 2 analysts, 0 (0%) are recommending DMAC as a Strong Buy, 2 (100%) are recommending DMAC as a Buy, 0 (0%) are recommending DMAC as a Hold, 0 (0%) are recommending DMAC as a Sell, and 0 (0%) are recommending DMAC as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year DMAC price target, the average DMAC price target is $7.00, with the highest DMAC stock price forecast at $8.00 and the lowest DMAC stock price forecast at $6.00.
On average, Wall Street analysts predict that Diamedica Therapeutics's share price could reach $7.00 by Mar 21, 2025. The average Diamedica Therapeutics stock price prediction forecasts a potential upside of 178.88% from the current DMAC share price of $2.51.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.